Research & Development
Harbour BioMed's partner Spruce Biosciences separates CRHX-101 into Adrenyx Biosciences
18 November 2026 -

Chinese biopharmaceutical company Harbour BioMed (HKEX:02142) announced on Tuesday that its partner Spruce Biosciences (Nasdaq:SPRB) has separated its CRHX-101 (formerly SPR-202 and HBM9013) programme into Adrenyx Biosciences.

Adrenyx is a newly established, wholly-owned subsidiary of Spruce focused on endocrinology. This company is expected to be listed on Nasdaq in the first half of 2027. Upon completion of the planned pro rata distribution of Adrenyx common stock to Spruce shareholders, Harbour BioMed expects to hold equity interests in both Spruce and Adrenyx.

CRHX-101 is a monoclonal antibody designed to selectively neutralise corticotropin-releasing hormone (CRH), an upstream driver of adrenal androgen excess in classic congenital adrenal hyperplasia (CAH). By targeting CRH at the top of the hormonal signalling cascade, CRHX-101 is being developed with the potential to achieve durable upstream disease control and reduce patients' reliance on chronic high-dose glucocorticoid therapy, a longstanding challenge in CAH management.

Adrenyx's near-term priorities include completion of IND-enabling nonclinical and chemistry, manufacturing and controls activities, the filing of an Investigational New Drug application for CRHX-101 with the US Food and Drug Administration (FDA), and initiation of a clinical program thereafter.

To support the development of CRHX-101, Adrenyx has secured an initial USD5m under a secured convertible note purchase arrangement, with the potential to issue up to USD10m in aggregate principal amount. In addition, a private placement of Adrenyx equity securities to institutional investors is expected to be completed in connection with the planned distribution, with up to USD50m funded by the convertible notes investor, inclusive of the notes funding.

CRHX-101 originated from HBM Alpha Therapeutics (HBMAT), an innovative biotechnology company incubated by Harbour BioMed.

In January 2025, HBMAT entered into a collaboration and license agreement with Spruce, granting Spruce exclusive rights to develop and commercialise this molecule outside Greater China (including mainland China, Hong Kong, Macau and Taiwan). Under the agreement, HBMAT is eligible to receive up to USD395m, including upfront, development, regulatory and commercial milestone payments, as well as tiered royalties on future net product sales.

Login
Username:

Password: